Benign Prostatic Hyperplasia Diagnosis and Treatment

Epidemiology and Prevalence

The American Urological Association notes that BPH is nearly ubiquitous in aging males, with increases starting at age 40-45 years, reaching 60% by age 60, and 80% by age 80 1
The prevalence of moderate-to-severe lower urinary tract symptoms (LUTS) rises to nearly 50% by age 80, with acute urinary retention increasing from 6.8 episodes per 1,000 patient years in the overall population to 34.7 episodes in men aged 70 and older 2
Approximately 90% of men between 45 and 80 years of age suffer some type of LUTS related to BPH 2

BPH contributes to urinary obstruction through two primary mechanisms: static component, which is direct bladder outlet obstruction (BOO) from enlarged prostatic tissue, and dynamic component, which is increased smooth muscle tone and resistance within the enlarged gland 1, 2
The T/DHT-androgen receptor complex within prostatic cells initiates transcription of DNA and translation, causing normal development, growth, and hyperplasia of the prostate 1
BPH develops due to an imbalance between growth and apoptosis (cellular death) in favor of growth, subsequently causing an increase in cellular mass 1

BPH-related urinary obstruction typically presents with storage symptoms, such as urgency, frequency, nocturia, and voiding symptoms, including weak stream, hesitancy, intermittency, straining, and sensation of incomplete emptying 3, 4

Initial evaluation should include medical history, physical examination (including digital rectal examination), International Prostate Symptom Score (IPSS), and urinalysis, as recommended by the American Urological Association 1, 5
Additional evaluations may include post-void residual (PVR) measurement and uroflowmetry 1

The American Urological Association recommends that alpha-adrenergic antagonists (alpha blockers) are first-line therapy for most men with moderate symptoms 1, 2
5-alpha reductase inhibitors (5ARIs) are effective for men with larger prostates (>30cc) 2
Transurethral resection of the prostate (TURP) remains the gold standard surgical approach, according to the American Urological Association 6

Acute urinary retention (AUR) is a significant complication, with risk increasing with age, as noted by the American Urological Association 2

BPH is rarely life-threatening, but its impact on quality of life can be significant, and treatment should be initiated based on symptom severity and degree of bother, as recommended by the American Urological Association 1, 2
Patients should be evaluated 4-12 weeks after initiating treatment to assess response, according to the American Urological Association 1

The urinalysis findings of trace leukocytes with negative culture suggest sterile inflammation, which can occur with prostatic enlargement causing bladder irritation rather than infection 7.
The proteinuria is mild and nonspecific, potentially related to concentrated urine or low-grade bladder/prostatic inflammation rather than primary renal disease 8.

The bilateral lower back pain is likely musculoskeletal or referred discomfort rather than indicating upper urinary tract pathology, especially given negative CVA tenderness 9.

Urinary tract infection is effectively ruled out by the negative urine culture despite trace leukocytes 7.
Upper urinary tract pathology is unlikely given negative CVA tenderness, no hematuria, and no history of stones 9.

Perform a digital rectal examination immediately to assess prostate size, consistency, and exclude nodules or induration that would suggest prostate cancer 7, 10.
Administer the International Prostate Symptom Score (IPSS) or AUA Symptom Index to objectively quantify symptom severity and bother, which will guide treatment decisions 8, 11.
Measure serum PSA in this patient with greater than 10-year life expectancy, as PSA helps exclude prostate cancer and predicts BPH progression risk 8, 10.

Obtain uroflowmetry to objectively assess voiding function and establish baseline flow parameters before considering any treatment 10.
Measure post-void residual (PVR) urine volume using bladder ultrasound to assess bladder emptying efficiency 10.
Complete a 3-day frequency-volume chart (bladder diary) given the prominent urinary frequency complaint, to quantify voiding patterns and exclude nocturnal polyuria 9, 11.

Do not assume infection based solely on trace leukocytes—the negative culture definitively excludes bacterial UTI, and empiric antibiotics are not indicated 7.
Do not overlook prostate cancer screening—PSA and DRE are essential in this age group to exclude malignancy as a cause of LUTS 8, 10.
Do not initiate alpha-blocker therapy without first documenting symptom severity with a validated questionnaire (IPSS/AUA-SI), as treatment indication depends on symptom bother, not just presence of symptoms 8, 11.
Do not order routine upper tract imaging or cystoscopy in this uncomplicated presentation—these tests have specific indications (hematuria, stones, prior surgery) not present in this case 9, 10.
Do not measure serum creatinine routinely—renal insufficiency from BPH occurs in well under 1% of patients and is typically due to other causes like diabetic nephropathy 8.